Kancera AB (publ) (ST:KAN) — Market Cap & Net Worth
Market Cap & Net Worth: Kancera AB (publ) (KAN)
Kancera AB (publ) (ST:KAN) has a market capitalization of $1.98 Million (Skr18.44 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #29694 globally and #693 in its home market, demonstrating a -37.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kancera AB (publ)'s stock price Skr0.15 by its total outstanding shares 121186228 (121.19 Million). Analyse KAN cash flow metrics to see how efficiently the company converts income to cash.
Kancera AB (publ) Market Cap History: 2015 to 2025
Kancera AB (publ)'s market capitalization history from 2015 to 2025. Data shows change from $391.82 Million to $1.98 Million (-41.31% CAGR).
Index Memberships
Kancera AB (publ) is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 0.01% | #233 of 281 |
Weight: Kancera AB (publ)'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kancera AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kancera AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1019.11x
Kancera AB (publ)'s market cap is 1019.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $391.82 Million | $282.00K | -$19.61 Million | 1389.44x | N/A |
| 2016 | $269.85 Million | $308.00K | -$22.31 Million | 876.13x | N/A |
| 2017 | $191.48 Million | $113.00K | -$56.20 Million | 1694.54x | N/A |
| 2018 | $90.73 Million | $358.00K | -$45.94 Million | 253.44x | N/A |
| 2019 | $47.64 Million | $3.22 Million | -$36.09 Million | 14.81x | N/A |
| 2020 | $179.98 Million | $90.00K | -$40.50 Million | 1999.79x | N/A |
| 2021 | $68.42 Million | $1.70 Million | -$45.69 Million | 40.15x | N/A |
| 2022 | $27.78 Million | $753.00K | -$52.48 Million | 36.89x | N/A |
| 2023 | $59.27 Million | $1.03 Million | -$64.89 Million | 57.27x | N/A |
| 2024 | $14.27 Million | $14.00K | -$44.57 Million | 1019.11x | N/A |
Competitor Companies of KAN by Market Capitalization
Companies near Kancera AB (publ) in the global market cap rankings as of May 4, 2026.
Key companies related to Kancera AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Kancera AB (publ) Historical Marketcap From 2015 to 2025
Between 2015 and today, Kancera AB (publ)'s market cap moved from $391.82 Million to $ 1.98 Million, with a yearly change of -41.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr1.98 Million | -86.09% |
| 2024 | Skr14.27 Million | -75.93% |
| 2023 | Skr59.27 Million | +113.38% |
| 2022 | Skr27.78 Million | -59.40% |
| 2021 | Skr68.42 Million | -61.98% |
| 2020 | Skr179.98 Million | +277.76% |
| 2019 | Skr47.64 Million | -47.49% |
| 2018 | Skr90.73 Million | -52.62% |
| 2017 | Skr191.48 Million | -29.04% |
| 2016 | Skr269.85 Million | -31.13% |
| 2015 | Skr391.82 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Kancera AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.98 Million USD |
| MoneyControl | $1.98 Million USD |
| MarketWatch | $1.98 Million USD |
| marketcap.company | $1.98 Million USD |
| Reuters | $1.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kancera AB (publ)
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the … Read more